MEK, P38, and PI-3K Mediate Cross Talk Between EGFR and TNFR in Enhancing Hepatocyte Growth Factor Production from Human Mesenchymal Stem Cells
Overview
Physiology
Authors
Affiliations
Human bone marrow mesenchymal stem cells (MSCs) are a potent source of growth factors, which are partly responsible for their beneficial paracrine effects. We reported previously that transforming growth factor-alpha (TGF-alpha), a putative mediator of wound healing and the injury response, increases the release of vascular endothelial growth factor (VEGF), augments tumor necrosis factor-alpha (TNF-alpha)-stimulated VEGF production, and activates mitogen-activated protein kinases and phosphatidylinositol 3-kinase (PI-3K) pathway in human MSCs. The experiments described in this report indicate that TGF-alpha increases MSC-derived hepatocyte growth factor (HGF) production. TGF-alpha-stimulated HGF production was abolished by inhibition of MEK, p38, PI-3K, or by small interfering RNA (siRNA) targeting TNF receptor 2 (TNFR2), but was not attenuated by siRNA targeting TNF receptor 1 (TNFR1). Ablation of TNFR1 significantly increased basal and stimulated HGF. A potent synergy between TGF-alpha and TNF-alpha was noted in MSC HGF production. This synergistic effect was abolished by MEK, P38, PI-3K inhibition, or by ablation of both TNF receptors using siRNA. We conclude that 1) novel cross talk occurs between tumor necrosis factor receptor and TGF-alpha/epidermal growth factor receptor in stimulating MSC HGF production; 2) this cross talk is mediated, at least partially, via activation of MEK, p38, and PI-3K; 3) TGF-alpha stimulates MSCs to produce HGF by MEK, p38, PI-3K, and TNFR2-dependent mechanisms; and 4) TNFR1 acts to decrease basal TGF-alpha and TNF-alpha-stimulated HGF.
Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.
Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.
PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.
Growth factors and growth factor gene therapies for treating chronic wounds.
Mullin J, Rahmani E, Kiick K, Sullivan M Bioeng Transl Med. 2024; 9(3):e10642.
PMID: 38818118 PMC: 11135157. DOI: 10.1002/btm2.10642.
Tavakoli S, Kisiel M, Biedermann T, Klar A Biomedicines. 2022; 10(1).
PMID: 35052797 PMC: 8773777. DOI: 10.3390/biomedicines10010118.
Song P, Han T, Xiang X, Wang Y, Fang H, Niu Y Stem Cell Res Ther. 2020; 11(1):178.
PMID: 32410702 PMC: 7227078. DOI: 10.1186/s13287-020-01691-x.
Tu J, Wan C, Zhang F, Cao L, Law P, Tian Y Aging Cell. 2020; 19(5):e13116.
PMID: 32320127 PMC: 7253065. DOI: 10.1111/acel.13116.